Company Performance Metrics
Edmundo Muniz: Founder- Neil William Flanzraich: Chairman of the Board and Chief Executive Officer
Kirax Corporation, a biopharmaceutical company, engages in acquiring, developing, and commercializing specialty care therapies to treat oncology, pain, inflammation, acute, and supportive care areas of unmet medical need. Its product pipeline includes AFP-464, an anti-cancer agent in patients with breast cancer; GGTI-2418, a synthetic
peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that appears to induce apoptosis by down-regulating several pivotal oncogenic and tumor survival pathways; and GFB-204, a calixarene derivative that is an inhibitor of VEGFR and PDGFR tyrosine phosphorylation. The company licenses or acquires rights to compounds in various stages of clinical development, as well as in-market products. Kirax Corporation was formerly known as Tigris Pharmaceuticals, Inc. The company was founded in 2005 and is based in Bonita Springs, Florida.
